Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia-Reference-Cited by-同舟云学术

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Published:2002-08 Issue:2 Volume:2 Page:117-125
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Shah Neil P.,Nicoll John M.,Nagar Bhushan,Gorre Mercedes E.,Paquette Ronald L.,Kuriyan John,Sawyers Charles L.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference34 articles.

1. An activating mutation in the ATP binding site of the ABL kinase domain;Allen;J. Biol. Chem.,1996

2. Roots of clinical resistance to STI-571 cancer therapy;Barthe;Science,2001

3. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR-ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance;Branford;Blood,2002

4. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210BCR/ABL protein;Daley;Proc. Natl. Acad. Sci. USA,1988

5. Induction of chronic myelogenous leukemia in mice by the P210 BCR-ABL gene of the Philadelphia chromosome;Daley;Science,1990

Cited by 1413 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Reversal of Drug Resistance in Cancer;Targets;2024-09-13

2. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib;Blood;2024-08-08

3. Vitamin C Supplementation in the Treatment of Autoimmune and Onco-Hematological Diseases: From Prophylaxis to Adjuvant Therapy;International Journal of Molecular Sciences;2024-07-02

4. Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance;Pharmacology Research & Perspectives;2024-06-21

5. Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population;Indian Journal of Hematology and Blood Transfusion;2024-06-21